Divesting the cord blood business will allow Natera to focus on its genetic testing business in reproductive health, oncology, and organ transplantation.
The company is forging ahead with its Signatera liquid biopsy circulating tumor DNA minimal residual disease (MRD) test and Prospera transplant assessment assay.
The company beat analyst estimates on the top and bottom line, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.
Two new studies of stage I to III CRC suggest that the presence of ctDNA in the months after surgery or chemotherapy can help identify patients who go on to relapse.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
